Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07737743) titled 'A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjogren's Disease' on July 27.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Sjogren's Disease
Intervention:
Drug: DDY391
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 27, 2026
Target Sample Size: 344
To know more, visit https://clinicaltrials.gov/study/NCT07737743
Discl...